Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease

Matteo Cotta Ramusino; Valentina Garibotto; Ruggero Bacchin; Daniele Altomare; Alessandra Dodich; Frederic Assal; Aline Mendes; Alfredo Costa; Michele Tinazzi; Silvia D Morbelli; Matteo Bauckneht; Agnese Picco; Massimo E Dottorini; Cristina Tranfaglia; Lucia Farotti; Nicola Salvadori; Davide Moretti; Giordano Savelli; Anna Tarallo; Flavio Nobili; Maura Parapini; Carlo Cavaliere; Elena Salvatore; Marco Salvatore; Marina Boccardi; Giovanni B Frisoni

doi:10.1007/s00259-019-04466-6

Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease

Matteo Cotta Ramusino, Valentina Garibotto, Ruggero Bacchin, Daniele Altomare, Alessandra Dodich, Frederic Assal, Aline Mendes, Alfredo Costa, Michele Tinazzi, Silvia D Morbelli, Matteo Bauckneht, Agnese Picco, Massimo E Dottorini, Cristina Tranfaglia, Lucia Farotti, Nicola Salvadori, Davide Moretti, Giordano Savelli, Anna Tarallo, Flavio NobiliMaura Parapini, Carlo Cavaliere, Elena Salvatore, Marco Salvatore, Marina Boccardi, Giovanni B Frisoni

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P

Original language	English
Journal	European Journal of Nuclear Medicine and Molecular Imaging
DOIs	https://doi.org/10.1007/s00259-019-04466-6
Publication status	Published - Aug 6 2019

Access to Document

10.1007/s00259-019-04466-6

Cite this

Ramusino, M. C., Garibotto, V., Bacchin, R., Altomare, D., Dodich, A., Assal, F., Mendes, A., Costa, A., Tinazzi, M., Morbelli, S. D., Bauckneht, M., Picco, A., Dottorini, M. E., Tranfaglia, C., Farotti, L., Salvadori, N., Moretti, D., Savelli, G., Tarallo, A., ... Frisoni, G. B. (2019). Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-019-04466-6

Ramusino, MC, Garibotto, V, Bacchin, R, Altomare, D, Dodich, A, Assal, F, Mendes, A, Costa, A, Tinazzi, M, Morbelli, SD , Bauckneht, M, Picco, A, Dottorini, ME, Tranfaglia, C, Farotti, L, Salvadori, N, Moretti, D, Savelli, G, Tarallo, A, Nobili, F, Parapini, M, Cavaliere, C, Salvatore, E, Salvatore, M, Boccardi, M & Frisoni, GB 2019, 'Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease', European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-019-04466-6

@article{2a269b25a50f4fed8efd2994ae3d7af5,

title = "Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease",

abstract = "PURPOSE: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P ",

author = "Ramusino, {Matteo Cotta} and Valentina Garibotto and Ruggero Bacchin and Daniele Altomare and Alessandra Dodich and Frederic Assal and Aline Mendes and Alfredo Costa and Michele Tinazzi and Morbelli, {Silvia D} and Matteo Bauckneht and Agnese Picco and Dottorini, {Massimo E} and Cristina Tranfaglia and Lucia Farotti and Nicola Salvadori and Davide Moretti and Giordano Savelli and Anna Tarallo and Flavio Nobili and Maura Parapini and Carlo Cavaliere and Elena Salvatore and Marco Salvatore and Marina Boccardi and Frisoni, {Giovanni B}",

year = "2019",

month = aug,

day = "6",

doi = "10.1007/s00259-019-04466-6",

language = "English",

journal = "European Journal of Pediatrics",

issn = "0340-6199",

publisher = "Springer Berlin Heidelberg",

}

TY - JOUR

T1 - Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease

AU - Ramusino, Matteo Cotta

AU - Garibotto, Valentina

AU - Bacchin, Ruggero

AU - Altomare, Daniele

AU - Dodich, Alessandra

AU - Assal, Frederic

AU - Mendes, Aline

AU - Costa, Alfredo

AU - Tinazzi, Michele

AU - Morbelli, Silvia D

AU - Bauckneht, Matteo

AU - Picco, Agnese

AU - Dottorini, Massimo E

AU - Tranfaglia, Cristina

AU - Farotti, Lucia

AU - Salvadori, Nicola

AU - Moretti, Davide

AU - Savelli, Giordano

AU - Tarallo, Anna

AU - Nobili, Flavio

AU - Parapini, Maura

AU - Cavaliere, Carlo

AU - Salvatore, Elena

AU - Salvatore, Marco

AU - Boccardi, Marina

AU - Frisoni, Giovanni B

PY - 2019/8/6

Y1 - 2019/8/6

N2 - PURPOSE: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P

AB - PURPOSE: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P

U2 - 10.1007/s00259-019-04466-6

DO - 10.1007/s00259-019-04466-6

M3 - Article

SN - 0340-6199

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

ER -

Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease

Abstract

Access to Document

Fingerprint

Cite this